Exercise of Warrants and Issue of Equity
Genflow Biosciences Plc has announced the exercise of warrants resulting in the issuance of 28,124,999 new ordinary shares, raising gross proceeds of £309,375. The exercise price was adjusted to 1.1p per share, and these new shares will rank pari passu with existing ordinary shares. Admission of these shares to the FCA official list and trading on the LSE main market is expected on or around October 2, 2026. Following this issuance, the Company's total issued share capital will increase to 594,534,781 shares.
Select text to share a quote on X · sign in to keep highlights & notes in your GENF notes
Genflow (LSE: GENF) (OTCQB: GENFF) ("Genflow" or the "Company"), a biotechnology company focused on the development of gene therapies for age-related diseases announces that it has received notices of exercise of warrants for a total of 28,124,999 new ordinary shares in the capital of the Company (the "Warrant Shares") with gross proceeds amounting to £309,375.
The Warrant Shares comprise 28,124,999 new ordinary shares being issued pursuant to the exercise of warrants granted and announced on 8 May 2025. As announced, the exercise price of these warrants ("Exercise Price") is subject to adjustment in certain circumstances, as set out in the warrant instrument, including a reset of the Exercise Price (as defined therein) if the Company completes a share issuance (or other transaction granting rights to subscribe for equity securities) during the Exercise Period (as defined therein) at a price lower than the Exercise Price. As such, the Exercise Price was adjusted to 1.1p. Subscription monies of £309,375 have been received by the Company in respect of this exercise.
Admission and Total Voting Rights
Application has been made for the Warrant Shares, which will rank pari passu in all respects with the existing Ordinary Shares of the Company, to be admitted to the FCA official list and to trading on the equity shares (transition) category of the Official List maintained by the FCA and to trading on the main market for listed securities of the LSE, which is expected to occur on or around 8.00 a.m. on 2 October 2026 ("Admission").
The total number of issued shares and the total number of voting rights in the Company, following Admission, will be 594,534,781.
The above figure of 594,534,781 should be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company, under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.